Johnson & Johnson’s (JNJ) Dividend Growth Record Strengthens its Role in Dividend Paying Stocks

Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dividend Paying Stocks to Buy Now.

Johnson & Johnson (NYSE:JNJ) is a major player in the pharmaceutical and medical device industries, with a recent market value close to $425 billion. The company is also showing growth, as second-quarter revenue increased 5.8% from the previous year and earnings rose 18%.

Until 2023, Johnson & Johnson (NYSE:JNJ) operated a strong consumer healthcare division that produced well-known products such as Tylenol and Band-Aid. That division was spun off into a separate company called Kenvue.

Johnson & Johnson (NYSE:JNJ)’s broad portfolio includes immunology treatments like Stelara and Tremfya, as well as cancer drugs such as Darzalex and Erleada. The company also has 40 programs currently in late-stage clinical trials. These trials are evaluating new drug candidates and seeking additional approvals for existing treatments like Stelara and Tremfya.

Johnson & Johnson (NYSE:JNJ) is popular among income investors because of its generous dividends. The company holds a 63-year track record of dividend growth, which makes it one of the best dividend paying stocks. Currently, it pays a quarterly dividend of $1.30 per share and has a dividend yield of 2.95%, as of September 19.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Consistent Dividend Stocks to Buy Now and Dividend Stock Portfolio For Income: 12 Stocks to Buy Now.

Disclosure: None.